

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED
中國中藥控股有限公司

(Incorporated in Hong Kong with limited liability)
(Stock Code: 570)

CHANGE OF NON-EXECUTIVE DIRECTORS

RESIGNATION OF NON-EXECUTIVE DIRECTORS

The board (the “**Board**”) of directors (the “**Directors**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Board resolved on 15 January 2025 that due to change of work arrangement, Mr. YANG Binghua, Mr. WANG Kan, Mr. MENG Qingxin, Ms. LI Ru, Mr. YANG Wenming and Mr. CHENG Xueren ceased to serve as the non-executive Directors with immediate effect. Upon resignation as non-executive Directors, Mr. YANG Binghua has also ceased to serve as a member of the nomination committee of the Board (the “**Nomination Committee**”) and Mr. YANG Wenming and Mr. CHENG Xueren have also ceased to serve as members of the strategic committee of the Board (the “**Strategic Committee**”).

Each of Mr. YANG Binghua, Mr. WANG Kan, Mr. MENG Qingxin, Ms. LI Ru, Mr. YANG Wenming and Mr. CHENG Xueren has confirmed that he/she has no disagreement with the Board and there is no matter relating to his/her resignation that needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to express its sincere gratitude to Mr. YANG Binghua, Mr. WANG Kan, Mr. MENG Qingxin, Ms. LI Ru, Mr. YANG Wenming and Mr. CHENG Xueren for their valuable contribution to the Group during their tenures of service.

APPOINTMENT OF NON-EXECUTIVE DIRECTORS

The Board is pleased to announce that:

- (i) Mr. LIU Haijian (“**Mr. LIU**”) has been appointed as a non-executive Director and a member of the Nomination Committee;
- (ii) Mr. LI Xiangrong (“**Mr. LI**”) has been appointed as a non-executive Director and a member of the Strategic Committee;
- (iii) Mr. ZU Jing (“**Mr. ZU**”) has been appointed as a non-executive Director and a member of the Strategic Committee;
- (iv) Ms. XU Jinghui (“**Ms. XU**”) has been appointed as a non-executive Director and a member of the audit committee of the Board; and
- (v) Mr. HUANG Hao (“**Mr. HUANG**”) has been appointed as a non-executive Director,

all with effect from 15 January 2025.

The biographical details of Mr. LIU, Mr. LI, Mr. ZU, Ms. XU and Mr. HUANG are set out below:

Mr. LIU Haijian, aged 50, master of military science of Shijiazhuang Army Command College of PLA, with qualification of assistant engineer. Mr. LIU served as the platoon leader of the Fifth Battalion of No. 1 General Communication Station of Beijing Military Region, the vice captain of No. 1 Equipment Technical Group of Beijing Military Region, a staff officer of communication department of Beijing Garrison Command; an associate section assistant of preliminary review and process management department of Patent Office of China National Intellectual Property Administration; the director of party mass department of China National Pharmaceutical Group Corporation (currently known as China National Pharmaceutical Group Co., Ltd., “**CNPGC**”); the deputy party secretary of Sinopharm Group Co. Ltd. (listed on the Stock Exchange, stock code: 01099) (“**Sinopharm Group**”) from January 2018 to October 2024. Mr. LIU has served as a full-time external director of CNPGC since October 2024.

Mr. LI Xiangrong, aged 54, bachelor of science and master of science of Peking University, with qualification of lectureship. Mr. LI is a member of Pharmaceutical Intellectual Property Research Professional Committee of Chinese Pharmaceutical Association. Mr. LI served as an assistant and lecturer of Peking University; a member of party leadership group and the deputy mayor of Jiangxi Jingtangshan Municipal People’s Government; the deputy director of industry management office of Peking University; the deputy manager of asset management department and the manager of planning and development department of China National Biotec Group Company Limited. He served as the director of board office of CNPGC for a long period since 2010. He was a director of Beijing Tiantan Biological Products Corporation Limited (listed on the Shanghai Stock Exchange, stock code:

600161) from October 2018 to May 2023 and the vice president and secretary of the board of China National Biotech Group Company Limited from February 2018 to November 2024. Mr. LI has served as a full-time external director of CNPGC since October 2024.

Mr. ZU Jing, aged 54, bachelor of economics of Beijing Economics College, with the qualification of senior accountant. Mr. ZU served as the deputy general manager of financial department of China National Service Corporation for Chinese Personnel Working Aboard, the deputy general manager and financial director of Zhongfu Jiayuan Trade Company (中服嘉遠貿易公司); the general manager of financial department, deputy financial director and financial director of China Sinopharm International Company (currently known as China Sinopharm International Corporation); the financial director of Shanghai Shyndec Pharmaceutical Co., Ltd. (listed on the Shanghai Stock Exchange, stock code: 600420); the director of the international cooperation department of CNPGC from April 2022 to March 2024. Mr. ZU has served as a full-time external director of CNPGC since October 2024.

Ms. XU Jinghui, aged 53, bachelor of industrial economics of Beijing University of Technology, master of business administration of Xiamen University, the holder of full senior accountant, certified public accountant, certified tax agent, international certified internal auditor. Ms. XU served as an accountant of Management Commission of Beijing Central Wholesale Market for Agricultural Products; the accounting assistant of Yukun information center of China Urban Planning and Design Institute; a senior auditor of Beijing Zhongzhou Guanghua Certified Public Accountants; the director assistant of financial department of CNPGC; the manager of financial department of Reed Sinopharm Exhibitions Co., Ltd.; the financial director of Bakery China Exhibitions Co., Ltd.; the financial director of China National Pharmaceutical Investment Co., Ltd.; the financial director of Sinopharm Group Finance Co., Ltd. from June 2016 to October 2024. Ms. XU has served as a full-time external director of CNPGC since October 2024.

Mr. HUANG Hao, aged 41, master of business administration of Swiss Geneva Business Institute, the holder of Chartered Financial Analyst and securities qualification certificate. Mr. HUANG served as a senior auditor of financial service in PricewaterhouseCoopers Zhong Tian CPAs Limited Company; a senior strategic analyst of planning department in Ping An Insurance (Group) Company of China, Ltd.; a senior investment manager of investment management department and corporation governance specialist of subsidiaries director resources department in Huawei Technologies Co., Ltd. He has successively served as the investment manager of private equity of Shanghai Huli Investment Management Co., Ltd. and deputy general manager of investment business of Ping An Shenye (Shanghai) Private Fund Management Partnership Enterprise LLP of China Ping An Insurance Overseas (Holdings) Limited from 2019 until now.

Mr. LIU, Mr. LI, Mr. ZU, Ms. XU and Mr. HUANG will individually enter into an appointment agreement with the Company in relation to their appointments as the non-executive Directors for an initial term of three years. They shall hold office only until the first annual general meeting of the Company after their appointments and shall then be eligible for re-election. Thereafter, they are subject to retirement by rotation and re-election in accordance with the articles of association of the

Company. Their Director's fees would be determined with reference to their performance and responsibilities, the Group's profitability and the prevailing market condition. According to the Company's current remuneration standard, it is expected that they will not receive any Director's fee.

Save as disclosed above, Mr. LIU, Mr. LI, Mr. ZU, Ms. XU and Mr. HUANG (i) do not hold any other position within the Group; (ii) have not held directorships in any other listed companies in the past three years; (iii) have not held any other major appointments and professional qualifications; and (iv) do not have any relationship with any Directors, senior management or substantial or controlling shareholders of the Company (as defined under the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")).

As at the date of this announcement, Mr. LIU, Mr. LI, Mr. ZU, Ms. XU and Mr. HUANG do not have any interest in the shares, underlying shares or debentures of the Company and/or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters concerning Mr. LIU, Mr. LI, Mr. ZU, Ms. XU and Mr. HUANG that need to be brought to the attention of the shareholders of the Company, nor is there any information relating to them that is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express welcome to Mr. LIU, Mr. LI, Mr. ZU, Ms. XU and Mr. HUANG for their appointments as the non-executive Directors.

By Order of the Board
China Traditional Chinese Medicine Holdings Co. Limited
YANG Jun
Chairman

Hong Kong, 15 January 2025

As at the date of this announcement, the Board comprises eleven Directors, of which Mr. YANG Jun and Mr. LI Hongjian are executive Directors; Mr. LIU Haijian, Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.